Skip to Content
Merck

Targeted Protein Degradation by Small Molecules.

Annual review of pharmacology and toxicology (2016-10-13)
Daniel P Bondeson, Craig M Crews
ABSTRACT

Protein homeostasis networks are highly regulated systems responsible for maintaining the health and productivity of cells. Whereas therapeutics have been developed to disrupt protein homeostasis, more recently identified techniques have been used to repurpose homeostatic networks to effect degradation of disease-relevant proteins. Here, we review recent advances in the use of small molecules to degrade proteins in a selective manner. First, we highlight all-small-molecule techniques with direct clinical application. Second, we describe techniques that may find broader acceptance in the biomedical research community that require little or no synthetic chemistry. In addition to serving as innovative research tools, these new approaches to control intracellular protein levels offer the potential to develop novel therapeutics targeting proteins that are not currently pharmaceutically vulnerable.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
L-Prolinamide, N-[3-[2-(2-aminoethoxy)ethoxy]-1-oxopropyl]-3-methyl-L-valyl-4-hydroxy-N-[[4-(4-methyl-5-thiazolyl)phenyl]methyl]-, (4R)- HCl, ≥95.0%
Sigma-Aldrich
VH 032 amide-alkyl C3-acid, ≥95%
Sigma-Aldrich
C5 Lenalidomide-C6-PEG1-C3-PEG1-Butyl NH2 hydrochloride, ≥95%
Sigma-Aldrich
2-(2,6-dioxopiperidin-3-yl)-5-(piperidin-4-yl)isoindole-1,3-dione hydrochloride, ≥95%
Sigma-Aldrich
(S,R,S)-AHPC-di-trimethylamide-dioxodisulfide-carbonate ester
Sigma-Aldrich
3-(3-Fluoro-4-piperidin-4-ylphenylamino)piperidine-2,6-dione hydrochloride, ≥95%
Sigma-Aldrich
(S,R,S)-VL285 Phenol-piperazine-pyridine-alkyne-NH2 hydrochloride
Sigma-Aldrich
L-Prolinamide, N-[2-[2-(carboxymethoxy)ethoxy]acetyl]-3-methyl-L-valyl-4-hydroxy-N-[[4-(4-methyl-5-thiazolyl)phenyl]methyl]-, (4R)-, ≥95%
Sigma-Aldrich
6F,C5-Pomalidomide-piperazine-piperidine-4-carbothioamide hydrochloride
Sigma-Aldrich
(S,R,S)-AHPC-CO-PEG4-C2-amine HCl, ≥95%
Sigma-Aldrich
C5 Lenalidomide-difluoroPEG1-C4-piperazine Hydrochloride, ≥95%
Sigma-Aldrich
Pomalidomide-PEG1-C2-azide, ≥95.0%
Sigma-Aldrich
2,6-Piperidinedione, 3-[(3-aminophenyl)amino] hydrochloride, ≥95%
Sigma-Aldrich
Thalidomide-4-hydroxyacetate, ≥95.0%
Sigma-Aldrich
Pomalidomide-piperazine-acetic acid, ≥95%
Sigma-Aldrich
(S,R,S)-AHPC-acetamido-O-PEG2-C1-acid, ≥95%
Sigma-Aldrich
4-Aminomethyl-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione hydrochloride, ≥95%
Sigma-Aldrich
Opto-thalidomide-O-acetamide-C4-NH2 hydrochloride
Sigma-Aldrich
Pomalidomide 4′-PEG3-amine hydrochloride, ≥95%
Sigma-Aldrich
3-((4-(Piperidin-4-yl)phenyl)amino)piperidine-2,6-dione hydrochloride, ≥95%
Sigma-Aldrich
1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-5-(4-piperidinyloxy) hydrochloride, ≥95%
Sigma-Aldrich
Pomalidomide acetic acid, ≥95.0%
Sigma-Aldrich
Opto-pomalidomide, ≥95%
Sigma-Aldrich
FBnG-C3-PEG3-C3-NH2 hydrochloride, ≥95%
Sigma-Aldrich
Pomalidomide-PEG1-C2-amine HCl, ≥95.0%
Sigma-Aldrich
Opto-pomalidomide-C2-NH2 hydrochloride, ≥95%
Sigma-Aldrich
1H-Isoindole-1,3(2H)-dione, 4-[(4-aminobutyl)amino]-2-(2,6-dioxo-3-piperidinyl)-, hydrochloride, ≥95%
Sigma-Aldrich
Pentanoic acid, 5-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]-, ≥95%
Sigma-Aldrich
Pomalidomide-PEG2-C2-NH2 hydrochloride, ≥95%
Sigma-Aldrich
3-[1,3-Dihydro-4-(4-hydroxy-1-butyn-1-yl)-1-oxo-2H-isoindol-2-yl]-2,6-piperidinedione, ≥95.0%